Skip to main content

Advertisement

SpringerLink
Log in

A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Based on the synergistic effect in preclinical studies, a phase I clinical trial for the combination of paclitaxel and doxifluridine (an intermetabolite of capecitabine) was performed to determine the recommended dose for the treatment of patients with metastatic gastric cancer.

Methods

The dose of paclitaxel was increased from 60 mg/m2 at level 1 to 90 mg/m2 at level 5. It was administered as a 1-h infusion on days 1 and 8. The dose of doxifluridine was fixed at 600 mg/m2 per day up to level 3, and escalated to 800 mg/m2 per day at levels 4 and 5. It was administered orally for 2 weeks. The treatment was repeated every 3 weeks.

Results

A total of 28 patients were enrolled. No dose-limiting toxicity (DLT) was observed at levels 1 and 2 (paclitaxel 70 mg/m2). A DLT of grade 4 neutropenia lasting for more than 4 days was observed in one patient at level 3 (paclitaxel 80 mg/m2). In addition, the first five of six patients in this group experienced grade 3 neutropenia during the first treatment cycle. A further six patients were added in order to confirm the safety of this dosage level, and no more DLTs except for grade 3 nausea in one patient were observed in the second cohort. No DLT was seen in three patients at level 4 (paclitaxel 80 mg/m2). DLTs (grade 3 neuropathy in one patient and a treatment delay of the second cycle for more than 1 week due to grade 3 neutropenia in another) were observed in two out of six patients at level 5 (paclitaxel 90 mg/m2), and this dose level was determined as the maximum tolerated dose. The tumor response rate was 42% (95% confidence interval 20–67%) in 19 patients with measurable lesions.

Conclusions

The recommended dose was determined as 80 mg/m2 of paclitaxel (days 1 and 8) and 800 mg/m2 of doxifluridine (days 1–14) every 3 weeks. The results of this phase I study are encouraging and a phase II trial is thus warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF (1998) Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J 4:269–274

    Google Scholar 

  2. Bajetta E, Colleoni M, Di Bartolomeo M, Buzzoni R, Bozzetti F, Doci R, Somma L, Cappuzzo F, Stampino CG, Guenzi A (1995) Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol 13:2613–2619

    Google Scholar 

  3. Bokemeyer C, Hartmann JT, Mayer F, Böhlke I, Kanz L, Von Pawel J, Derigs G, Schröder M (2000) UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors. Oncology 14:63–67

    Google Scholar 

  4. Bollag W, Hartmann HR (1980) Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine. Eur J Cancer 16:427–432

    Google Scholar 

  5. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9:307–310

    Google Scholar 

  6. Cook AF, Holman MJ, Kramer MJ, Trown PW (1979) Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 22:1330–1335

    Google Scholar 

  7. Di Bartolomeo M, Bajetta E, Somma L, Carnaghi C, Bandieri E, Del Vecchio M, Gallo Stampino C, Buzzoni R (1996) Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Oncology 53:54–57

    Google Scholar 

  8. Eisenhauer EA (1998) Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16–19 June 1998. Ann Oncol 9:1047–1052

    Google Scholar 

  9. Glimelius B, Hoffman K, Haglund U, Nyrèn O, Sjödén PO (1994) Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189–190

    Google Scholar 

  10. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797–1805

    Google Scholar 

  11. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C (2002) Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 13:497–503

    Google Scholar 

  12. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB (1980) Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 71:112–123

    Google Scholar 

  13. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813–3818

    Google Scholar 

  14. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS (1999) Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85:295–301

    Article  CAS  PubMed  Google Scholar 

  15. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T (2003) A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64:232–236

    Google Scholar 

  16. Löffler TM, Freund W, Lipke J, Hausamen TU (1996) Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin Oncol 23:32–34

    Google Scholar 

  17. Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235–242

    Google Scholar 

  18. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273–279

    CAS  PubMed  Google Scholar 

  19. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384–388

    Google Scholar 

  20. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, Ohta K, Yoshida Y, Kimura T, Kurihara M (1985) Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with malignant cancer—a multi-institutional cooperative study. Gan To Kagaku Ryoho 12:2044–2051

    Google Scholar 

  21. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T (1998) An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21:416–419

    Google Scholar 

  22. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54–59

    Google Scholar 

  23. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591

    Google Scholar 

  24. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, Parö G (2002) Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 41:418–424

    Google Scholar 

  25. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715–1720

    Article  CAS  PubMed  Google Scholar 

  26. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019

    Google Scholar 

  27. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353–3361

    Google Scholar 

  28. Shimada Y (1998) Clinical trials for advanced gastrointestinal cancers in Japan. Japan Clinical Oncology Group Gastrointestinal Oncology Study Group. Cancer Chemother Pharmacol [Suppl] 42:S80–S84

    Google Scholar 

  29. Tamura T, Sasaki Y, Nishiwaki Y, Saijo N (1995) Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86:1203–1209

    Google Scholar 

  30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  31. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648–2657

    Google Scholar 

  32. Wakui A (1988) Phase II study of 5′-deoxy-5-fluororidine in the treatment of gastric cancer. J Int Med Res 16:17B–18B

    Google Scholar 

  33. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T (2001) Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12:1133–1137

    Google Scholar 

Download references

Acknowledgements

We thank Miss Noriko Amano for data management. This study was supported in part by a Grant-in-Aid (S14-3) from the Ministry of Health, Labor and Welfare, Japan.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama, Ehime, 790-0007, Japan

    Toshikazu Moriwaki, Ichinosuke Hyodo, Tomohiro Nishina, Ken Hirao, Takao Tsuzuki, Satoshi Hidaka, Takeshi Kajiwara, Shinji Endo, Junichirou Nasu, Shoji Hirasaki & Toshikazu Masumoto

  2. Department of Surgical Oncology, National Shikoku Cancer Center, Matsuyama, Japan

    Akira Kurita

Authors
  1. Toshikazu Moriwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ichinosuke Hyodo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomohiro Nishina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ken Hirao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takao Tsuzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Satoshi Hidaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takeshi Kajiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shinji Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junichirou Nasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shoji Hirasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshikazu Masumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Akira Kurita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ichinosuke Hyodo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moriwaki, T., Hyodo, I., Nishina, T. et al. A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer. Cancer Chemother Pharmacol 56, 138–144 (2005). https://doi.org/10.1007/s00280-004-0983-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0983-y

Keywords

Search

Navigation